Biogen’s Tau-Focused Alzheimer’s Drug Shows Mixed Results in Mid-Stage Trial: Cognitive Benefit at Lowest Dose, But Study Misses Primary Goal

Breaking: Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise and Pitfalls in Mid-Stage Trial

Cambridge, MA — Biogen announced today that its experimental tau-targeting Alzheimer’s drug, diranersen (BIIB080), reduced toxic tau protein levels in the brain and spinal fluid of early-stage Alzheimer’s patients—and those reductions correlated with a slowing of cognitive decline. However, the Phase 2 study failed its primary efficacy endpoint because the lowest dose produced the strongest benefits, undermining the expected dose-response pattern.

“We are encouraged by the signal of cognitive slowing, but the unexpected dose-response curve means we need to carefully design the next phase of development,” said Dr. Samantha Lane, Biogen’s Vice President of Neuroscience Development, in a statement.

Key Findings

Diranersen, an antisense oligonucleotide, targets the tau protein—a toxic aggregator that, like amyloid, is believed to drive neurodegeneration. The trial enrolled patients with early-stage Alzheimer’s and tested three escalating doses over 12 months.

Results showed the lowest dose produced the greatest reduction in tau levels in cerebrospinal fluid and brain tissue. That same dose also correlated with a statistically significant slowing of cognitive decline. Higher doses, paradoxically, showed less benefit.

Because the study’s primary goal was a clear dose-response—where larger doses yield greater effects—it failed on that measure. “You can’t declare victory when the lowest dose works best and the highest doses don’t,” said Dr. Mark Henderson, a Alzheimer’s researcher at Georgetown University, not involved in the trial. “But you also can’t ignore a cognitive signal, especially in this field.”

Background: Tau Versus Amyloid

Tau is a microtubule-stabilizing protein that, when hyperphosphorylated, forms toxic tangles inside neurons. For decades, most Alzheimer’s drug development focused on amyloid beta plaques, the other hallmark pathology. Biogen itself had a controversial journey with its amyloid-targeting drug Aduhelm, which received accelerated FDA approval in 2021 but faced reimbursement and efficacy challenges.

Diranersen is part of a new wave of tau-directed therapies. Unlike amyloid drugs that clear plaques, tau-targeting approaches aim to prevent or remove the tangles that correlate more tightly with cognitive loss. “This is a fundamentally different mechanism, and the field has been eagerly awaiting tau data,” explained Dr. Lane.

The Phase 2 study enrolled 120 participants across 30 sites in the U.S. and Europe. Safety data were consistent with previous studies; the most common adverse events were injection-site reactions and headache.

What This Means

For patients and families: the mixed results offer a glimmer of hope—the first tau-targeted drug to show a cognitive benefit in a controlled study—but also highlight the complexity of Alzheimer’s biology. “If lower doses are better, we may need to rethink dosing strategies for this class entirely,” said Dr. Henderson.

For Biogen: the company now faces a strategic decision. Should it advance diranersen into Phase 3 using only the lowest dose, which would require a larger and potentially longer trial to confirm the signal? Or will it pivot back to its amyloid programs, which remain under regulatory scrutiny?

For the Alzheimer’s drug development pipeline: the data underscore that tau remains a viable but tricky target. The failure of a clear dose-response could delay approval pathways but does not sink the entire program. “This is exactly the kind of data you want to see before committing hundreds of millions of dollars to a pivotal trial,” noted Dr. Rebecca Kwok, an analyst at Global Neuro Research.

Biogen plans to present full results at an upcoming medical conference and discuss next steps with regulators. The company’s stock fluctuated in after-hours trading, reflecting the mixed nature of the data.

Quick Facts

• Drug: diranersen (BIIB080) — antisense oligonucleotide targeting tau mRNA
• Trial Phase: Phase 2, randomized, placebo-controlled
• Primary endpoint: Dose-response on tau reduction at 12 months – not met
• Secondary endpoint: Cognitive decline (CDR-SB) – positive signal at lowest dose
• Patient population: Early-stage Alzheimer’s (mild cognitive impairment or mild dementia)

Updated at 4:30 PM ET — This is a developing story.